• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    8/24/23 5:32:05 PM ET
    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • YS Biopharma Co (NASDAQ:YS) stock rose 43.0% to $1.08 during Thursday's after-market session. Today's trading volume for this security ended up closing at 1.6 million shares, which is 267.1 percent of its average volume over the last 100 days. The company's market cap stands at $100.5 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) shares rose 10.3% to $0.64. The market value of their outstanding shares is at $11.0 million.
    • Modular Medical (NASDAQ:MODD) shares moved upwards by 6.25% to $1.36. The company's market cap stands at $28.6 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 6.24% to $0.85. The market value of their outstanding shares is at $192.2 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares rose 4.99% to $3.78. The company's market cap stands at $208.4 million.
    • Singular Genomics Sys (NASDAQ:OMIC) stock rose 4.99% to $0.49. The market value of their outstanding shares is at $36.1 million.

    Losers

    • Myomo (AMEX:MYO) stock fell 18.7% to $0.61 during Thursday's after-market session. At the close, Myomo's trading volume reached 151.2K shares. This is 39.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.8 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) stock decreased by 10.26% to $0.49. The market value of their outstanding shares is at $49.5 million.
    • Minerva Surgical (NASDAQ:UTRS) shares decreased by 8.0% to $0.23. Today's trading volume for this security ended up closing at 1.1 million shares, which is 27.2 percent of its average volume over the last 100 days. The company's market cap stands at $40.8 million.
    • SeqLL (NASDAQ:SQL) stock fell 7.92% to $0.3. The company's market cap stands at $4.1 million.
    • Nemaura Medical (NASDAQ:NMRD) shares fell 7.6% to $0.55. The company's market cap stands at $15.7 million.
    • Cue Health (NASDAQ:HLTH) shares decreased by 7.01% to $0.5. Trading volume for this security closed at 52.2K, accounting for 5.8% of its average full-day volume over the last 100 days. The company's market cap stands at $77.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $AGLE
    $HLTH
    $LSDI

    CompanyDatePrice TargetRatingAnalyst
    Adaptimmune Therapeutics plc
    $ADAP
    7/29/2025Buy → Neutral
    H.C. Wainwright
    Adaptimmune Therapeutics plc
    $ADAP
    6/26/2025$0.50Outperform → Neutral
    Mizuho
    Omega Therapeutics Inc.
    $OMGA
    11/15/2024Outperform → Mkt Perform
    Raymond James
    Myomo Inc.
    $MYO
    7/31/2024$7.00Buy
    Craig Hallum
    Adaptimmune Therapeutics plc
    $ADAP
    7/30/2024$4.00Buy
    H.C. Wainwright
    Omega Therapeutics Inc.
    $OMGA
    6/18/2024$12.00Outperform
    Raymond James
    Adaptimmune Therapeutics plc
    $ADAP
    5/30/2024$3.15Sector Outperform
    Scotiabank
    Myomo Inc.
    $MYO
    5/20/2024$7.00Buy
    Lake Street
    More analyst ratings

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    SEC Filings

    View All

    SEC Form S-8 filed by Modular Medical Inc.

    S-8 - Modular Medical, Inc. (0001074871) (Filer)

    3/17/26 5:10:47 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Inc. filed SEC Form 8-K: Other Events

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/13/26 4:00:48 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Myomo Inc.

    S-8 - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:49:09 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80 million. These a

    3/9/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Getz Heather C bought $50,960 worth of shares (70,000 units at $0.73), increasing direct ownership by 168% to 111,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/12/26 5:18:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Getz Heather C bought $50,960 worth of shares (70,000 units at $0.73), increasing direct ownership by 168% to 111,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/12/26 5:18:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adaptimmune Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adaptimmune Therapeutics from Buy to Neutral

    7/29/25 7:36:15 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptimmune Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Adaptimmune Therapeutics from Outperform to Neutral and set a new price target of $0.50

    6/26/25 7:50:31 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Omega Therapeutics downgraded by Raymond James

    Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform

    11/15/24 9:11:43 AM ET
    $OMGA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Financials

    Live finance-specific insights

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports Third Quarter 2025 Financial and Operating Results

    Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decrease

    11/10/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Leadership Updates

    Live Leadership Updates

    View All

    $ADAP
    $AGLE
    $HLTH
    $LSDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Adaptimmune Reports Q1 Financial Results and Provides Business Update

    TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026Adaptimmune had Total Liquidity1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March

    5/13/25 7:30:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

    5/7/25 12:00:00 PM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptimmune Provides Q4 and Full Year 2024 Business Update

    TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

    3/20/25 7:00:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/22/24 7:55:51 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Adaptimmune Therapeutics plc

    SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)

    11/13/24 9:04:55 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care